Updated Aug 13 at 11:26am ET.
Follow Aflac to never miss an important update.
Aflac earned $1.75 per share this quarter, a small drop from last year. Total revenue reached $4.12 billion, which was slightly ahead of what analysts expected. The company earns a huge portion of its money in Japan, so when the U.S. dollar is strong, those yen-based profits are worth less when brought back home. This currency shift was the main reason for the slight profit dip.
Despite the currency pressure, the business remains a steady cash generator. Aflac returned $1.3 billion to its owners this quarter through dividends and buybacks, which is when a company buys its own shares to make the remaining ones more valuable. For long-term owners, the focus remains on whether Aflac can keep selling new policies in Japan's aging market while growing its presence in U.S. offices.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company reports its second-quarter results today. Analysts are looking for revenue of about 4.11 billion dollars. Beyond the headline numbers, the most important thing to watch is the performance of the Japan business, which provides the bulk of the company's profit.
We will also be looking for updates on sales growth in the U.S. workplace. Aflac relies on adding small-business customers in the U.S. to balance out its more mature market in Japan. Any significant shift in the value of the Japanese yen is also worth noting, as it can change how much the company's overseas earnings are worth when brought back to the U.S.
The U.S. and Japan recently acted together to support the value of the Japanese yen. This matters for Aflac because it earns a huge portion of its profit in Japan. When the yen is weak, those earnings are worth fewer dollars; when the yen strengthens, those same earnings look better on the company's U.S. financial statements.
While this intervention helps stabilize the currency, it highlights the company's heavy reliance on Japan. Long-term owners should watch how these currency swings affect the cash the company has available for dividends and buying back its own shares.
Source: Market Watch
Aflac's latest wellness survey shows a shift in how younger people handle healthcare, with 76 percent of Gen Z respondents using AI for initial health support. The data also suggests these groups are spending more on self-care but are less likely to have a primary care doctor. While this is just a survey, it helps Aflac understand the habits of its future customers. Since Aflac sells supplemental insurance, which pays cash directly to patients for out-of-pocket costs, understanding how people seek care helps the company design and market its policies to a younger workforce.
Source: PRNewsWire
Jefferies analysts raised their price target for the stock to $108. This suggests they see the company as fairly valued at current levels rather than a bargain. The firm kept its Hold rating, which is a signal that they do not see a strong reason to buy or sell the stock right now.
Source: Jefferies
Analysts recently adjusted their price targets following the company's second-quarter earnings report. Most analysts are neutral, with 23 of 32 holding a non-bullish rating and the average target of $118 sitting slightly below the current stock price.
Aflac has a mixed record lately, missing analyst targets in four of the last eight quarters as shifting currency values make its results harder to predict.
| Expectation | |
|---|---|
| EPS | $1.80 |
| Revenue | $4.07B |
